US5993434A
(en)
*
|
1993-04-01 |
1999-11-30 |
Genetronics, Inc. |
Method of treatment using electroporation mediated delivery of drugs and genes
|
US5702359A
(en)
*
|
1995-06-06 |
1997-12-30 |
Genetronics, Inc. |
Needle electrodes for mediated delivery of drugs and genes
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
PL337583A1
(en)
|
1997-06-30 |
2000-08-28 |
Rhone Poulenc Rorer Sa |
Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method
|
PL337584A1
(en)
|
1997-06-30 |
2000-08-28 |
Rhone Poulenc Rorer Sa |
Improved method of transferring nucleic acid to eucariotic cells of multiple-cell organisms and connection enabling accomplishment of this method
|
US6241701B1
(en)
|
1997-08-01 |
2001-06-05 |
Genetronics, Inc. |
Apparatus for electroporation mediated delivery of drugs and genes
|
US6055453A
(en)
|
1997-08-01 |
2000-04-25 |
Genetronics, Inc. |
Apparatus for addressing needle array electrodes for electroporation therapy
|
US20040229363A1
(en)
*
|
1998-06-24 |
2004-11-18 |
Ed Nolan |
High efficiency transfection based on low electric field strength, long pulse length
|
EP1100579B1
(en)
|
1998-07-13 |
2015-09-02 |
Inovio Pharmaceuticals, Inc. |
Skin and muscle-targeted gene therapy by pulsed electrical field
|
US7922709B2
(en)
|
1998-07-13 |
2011-04-12 |
Genetronics, Inc. |
Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
|
US6678556B1
(en)
*
|
1998-07-13 |
2004-01-13 |
Genetronics, Inc. |
Electrical field therapy with reduced histopathological change in muscle
|
AU2868200A
(en)
*
|
1999-02-08 |
2000-08-25 |
Chiron Corporation |
Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
|
US6593130B1
(en)
|
1999-04-16 |
2003-07-15 |
The Regents Of The University Of California |
Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy
|
AU2001241958A1
(en)
*
|
2000-03-03 |
2001-09-17 |
Valentis, Inc. |
Improved poloxamer and poloxamine compositions for nucleic acid delivery
|
CA2409603A1
(en)
|
2000-05-22 |
2001-11-29 |
Merck & Company, Inc. |
System and method for assessing the performance of a pharmaceutical agent delivery system
|
US6733485B1
(en)
|
2001-05-25 |
2004-05-11 |
Advanced Bionics Corporation |
Microstimulator-based electrochemotherapy methods and systems
|
US20040204669A1
(en)
*
|
2001-07-05 |
2004-10-14 |
Hofmann Gunter A. |
Apparatus for electroporation mediated delivery for drugs and genes
|
US7713740B2
(en)
*
|
2001-08-24 |
2010-05-11 |
University Of South Florida |
Method of using electric fields to facilitate the entry of molecules into cells in vivo
|
AU2002337840B2
(en)
|
2001-10-11 |
2007-08-09 |
Msd Italia S.R.L. |
Hepatitis C virus vaccine
|
DE60236364D1
(en)
|
2001-10-11 |
2010-06-24 |
Angeletti P Ist Richerche Bio |
Hepatitis-c-virus-impfstoff
|
CA2465476A1
(en)
*
|
2001-11-08 |
2003-05-15 |
The Regents Of The University Of California |
Methods and compositions for correction of cardiac conduction disturbances
|
KR20040075003A
(en)
*
|
2001-12-14 |
2004-08-26 |
제네트로닉스, 인코포레이티드 |
Methods For Particle-Assisted Polynucleotide Immunization Using A Pulsed Electric field
|
EP1470161A1
(en)
*
|
2002-01-18 |
2004-10-27 |
Inovio AS |
Bispecific antibody dna constructs for intramuscular administration
|
US8209006B2
(en)
|
2002-03-07 |
2012-06-26 |
Vgx Pharmaceuticals, Inc. |
Constant current electroporation device and methods of use
|
US7245963B2
(en)
*
|
2002-03-07 |
2007-07-17 |
Advisys, Inc. |
Electrode assembly for constant-current electroporation and use
|
JP2005518904A
(en)
|
2002-03-07 |
2005-06-30 |
マーク アンド カンパニー インコーポレイテッド |
Clinical syringe with electrical stimulation aspect
|
US6912417B1
(en)
*
|
2002-04-05 |
2005-06-28 |
Ichor Medical Systmes, Inc. |
Method and apparatus for delivery of therapeutic agents
|
CN100455328C
(en)
|
2002-04-16 |
2009-01-28 |
塞托·帕尔斯科技公司 |
Method of treating biological materials with translating electrical fields and electrode polarity reversal
|
US20040106896A1
(en)
*
|
2002-11-29 |
2004-06-03 |
The Regents Of The University Of California |
System and method for forming a non-ablative cardiac conduction block
|
US7328064B2
(en)
|
2002-07-04 |
2008-02-05 |
Inovio As |
Electroporation device and injection apparatus
|
EP1729848B1
(en)
|
2004-03-08 |
2015-04-29 |
Ichor Medical Systems Inc. |
Improved apparatus for electrically mediated delivery of therapeutic agents
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
CN101119735A
(en)
*
|
2005-03-19 |
2008-02-06 |
加利福尼亚大学董事会 |
Ultra low strength electric field network-mediated ex vivo gene, protein and drug delivery in cells
|
EP1893636A2
(en)
|
2005-06-17 |
2008-03-05 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Hepatitis c virus nucleic acid vaccine
|
DK1984007T3
(en)
*
|
2006-02-13 |
2015-12-07 |
Oncolytics Biotech Inc |
Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
|
US20100285040A1
(en)
|
2006-11-17 |
2010-11-11 |
Iacob Mathiesen |
Methods of enhancing immune response using electroporation-assisted vaccination and boosting
|
WO2009058564A2
(en)
|
2007-11-01 |
2009-05-07 |
Maxygen, Inc. |
Immunosuppressive polypeptides and nucleic acids
|
CA2720168A1
(en)
|
2008-04-04 |
2009-10-08 |
David B. Weiner |
A composition, system and method for removal of detergents from aqueous solutions
|
AU2009231559B2
(en)
*
|
2008-04-04 |
2015-10-22 |
The Trustees Of The University Of Pennsylvania |
Consensus sequences of Chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
|
EP2147697A1
(en)
|
2008-07-21 |
2010-01-27 |
Centre National De La Recherche Scientifique-CNRS |
Process and device for applying electric fields into conductive material
|
EP2156860A1
(en)
|
2008-08-20 |
2010-02-24 |
Centre National De La Recherche Scientifique-CNRS |
Method for producing insulated electrodes for applying electric fields into conductive material
|
US20100298697A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Medtronic, Inc. |
Method and devices for improved efficiency of rna delivery to cells
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
EP2477659A4
(en)
|
2009-09-14 |
2014-01-15 |
Univ Pennsylvania |
Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
|
KR20210149203A
(en)
|
2009-11-02 |
2021-12-08 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
|
US8298820B2
(en)
|
2010-01-26 |
2012-10-30 |
The Trustees Of The University Of Pennsylvania |
Influenza nucleic acid molecules and vaccines made therefrom
|
AU2011213559B2
(en)
|
2010-02-08 |
2015-05-07 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
|
KR20180096814A
(en)
|
2010-09-27 |
2018-08-29 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Consensus antigen constructs and vaccines made there from, and methods of using same to treat malaria
|
BR112013011705B1
(en)
|
2010-11-12 |
2022-04-05 |
The Trustees Of The University Of Pennsylvania |
Consensus prostate antigens, nucleic acid molecule encoding the same, and vaccine and uses comprising the same
|
CA2826199A1
(en)
|
2011-01-31 |
2012-08-09 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
|
EA037377B1
(en)
|
2011-02-11 |
2021-03-22 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Vaccine for inducing an immune response against hbv
|
US9238679B2
(en)
|
2011-02-11 |
2016-01-19 |
The Trustees Of The University Of Pennslyvania |
Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
|
WO2012172424A1
(en)
|
2011-06-15 |
2012-12-20 |
Crontech Pharma Ab |
Injection needle and device
|
ES2758713T3
(en)
|
2011-07-11 |
2020-05-06 |
Inovio Pharmaceuticals Inc |
Lassa virus DNA vaccine
|
CA2858884A1
(en)
|
2011-12-12 |
2013-06-20 |
The Trustees Of The University Of Pennsylvania |
Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections
|
BR112014014078A8
(en)
|
2011-12-12 |
2021-09-28 |
The Trustees Of The Univ Of Pennsylvania |
Compositions comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
|
KR20140146651A
(en)
|
2012-04-10 |
2014-12-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
|
EP4190350A1
(en)
|
2012-04-12 |
2023-06-07 |
The Trustees Of The University Of Pennsylvania |
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
|
DE102012013534B3
(en)
|
2012-07-05 |
2013-09-19 |
Tobias Sokolowski |
Apparatus for repetitive nerve stimulation for the degradation of adipose tissue by means of inductive magnetic fields
|
WO2014064534A2
(en)
|
2012-10-05 |
2014-05-01 |
Chrontech Pharma Ab |
Injection needle, device, immunogenic compositions and method of use
|
JP6523174B2
(en)
|
2012-12-13 |
2019-05-29 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
WT1 vaccine
|
MX2015011487A
(en)
|
2013-03-15 |
2016-02-03 |
Univ Pennsylvania |
Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom.
|
CA2898126A1
(en)
|
2013-03-15 |
2014-09-18 |
The Trustees Of The University Of Pennsylvania |
Cancer vaccines and methods of treatment using the same
|
DK3028048T3
(en)
|
2013-07-31 |
2019-01-21 |
Bioventures Llc |
COMPOSITIONS FOR TREATMENT AND PREVENTION OF CANCER TARGETING AGAINST TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN
|
SG11201604719WA
(en)
|
2013-12-13 |
2016-07-28 |
Univ Pennsylvania |
Dna antibody constructs and method of using same
|
JP7268958B2
(en)
|
2014-12-01 |
2023-05-08 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
DNA antibody constructs and methods of use thereof
|
US11491342B2
(en)
|
2015-07-01 |
2022-11-08 |
Btl Medical Solutions A.S. |
Magnetic stimulation methods and devices for therapeutic treatments
|
US20180001107A1
(en)
|
2016-07-01 |
2018-01-04 |
Btl Holdings Limited |
Aesthetic method of biological structure treatment by magnetic field
|
US10695575B1
(en)
|
2016-05-10 |
2020-06-30 |
Btl Medical Technologies S.R.O. |
Aesthetic method of biological structure treatment by magnetic field
|
US11266850B2
(en)
|
2015-07-01 |
2022-03-08 |
Btl Healthcare Technologies A.S. |
High power time varying magnetic field therapy
|
WO2017055522A1
(en)
|
2015-09-29 |
2017-04-06 |
Academisch Medisch Centrum |
Stabilized env proteins of hiv
|
US11253717B2
(en)
|
2015-10-29 |
2022-02-22 |
Btl Healthcare Technologies A.S. |
Aesthetic method of biological structure treatment by magnetic field
|
JP7123800B2
(en)
|
2016-02-05 |
2022-08-23 |
イノビオ ファーマシューティカルズ,インコーポレイティド |
Cancer vaccine and method of treatment therewith
|
JP6910075B2
(en)
|
2016-03-28 |
2021-07-28 |
イコル メディカル システムズ,インク. |
Methods and devices for delivery of therapeutic agents
|
WO2017180770A1
(en)
|
2016-04-13 |
2017-10-19 |
Synthetic Genomics, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
US11247039B2
(en)
|
2016-05-03 |
2022-02-15 |
Btl Healthcare Technologies A.S. |
Device including RF source of energy and vacuum system
|
US11464993B2
(en)
|
2016-05-03 |
2022-10-11 |
Btl Healthcare Technologies A.S. |
Device including RF source of energy and vacuum system
|
US11534619B2
(en)
|
2016-05-10 |
2022-12-27 |
Btl Medical Solutions A.S. |
Aesthetic method of biological structure treatment by magnetic field
|
US10583287B2
(en)
|
2016-05-23 |
2020-03-10 |
Btl Medical Technologies S.R.O. |
Systems and methods for tissue treatment
|
US10556122B1
(en)
|
2016-07-01 |
2020-02-11 |
Btl Medical Technologies S.R.O. |
Aesthetic method of biological structure treatment by magnetic field
|
MX2019004499A
(en)
|
2016-10-17 |
2019-11-18 |
Janssen Pharmaceuticals Inc Star |
Recombinant virus replicon systems and uses thereof.
|
US11845939B2
(en)
|
2016-12-05 |
2023-12-19 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for enhancing gene expression
|
US11344618B2
(en)
|
2017-08-26 |
2022-05-31 |
Academisch Medisch Centrum |
HIV envelope glycoprotein immunogens
|
CA3083532C
(en)
|
2017-12-13 |
2023-09-05 |
Inovio Pharmaceuticals, Inc. |
Cancer vaccines targeting prame and uses thereof
|
US11235044B2
(en)
|
2017-12-13 |
2022-02-01 |
Inovio Pharmaceuticals, Inc. |
Cancer vaccines targeting MUC16 and uses thereof
|
KR102637862B1
(en)
|
2017-12-13 |
2024-02-19 |
이노비오 파마수티컬즈, 인크. |
Cancer vaccines targeting mesothelin and uses thereof
|
WO2019123250A1
(en)
|
2017-12-19 |
2019-06-27 |
Janssen Sciences Ireland Unlimited Company |
Methods and compositions for inducing an immune response against hepatitis b virus (hbv)
|
EA202091516A1
(en)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
|
EA202091517A1
(en)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
METHODS AND DEVICE FOR DELIVERY OF VACCINES AGAINST HEPATITIS B VIRUS (HBV)
|
MA51311A
(en)
|
2017-12-19 |
2020-10-28 |
Janssen Sciences Ireland Unlimited Co |
HEPATITIS B VIRUS (HBV) VACCINES AND RELATED USES
|
EA202091513A1
(en)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
|
JP2021511318A
(en)
|
2018-01-19 |
2021-05-06 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
Induction and enhancement of immune response using recombinant replicon system
|
EP3721939B1
(en)
|
2019-04-11 |
2022-07-06 |
BTL Healthcare Technologies a.s. |
Device for aesthetic treatment of biological structures by radiofrequency and magnetic energy
|
CA3140708A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
EP3986562A1
(en)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
|
WO2020255014A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Recombinant interleukin 12 construct and uses thereof
|
US20220233685A1
(en)
|
2019-06-18 |
2022-07-28 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
|
US20220249647A1
(en)
|
2019-06-18 |
2022-08-11 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
WO2020254876A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Virus-like particle delivery of hepatitis b virus (hbv) vaccines
|
US20220233526A1
(en)
|
2019-06-18 |
2022-07-28 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
WO2020255012A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
|
US20220241402A1
(en)
|
2019-06-18 |
2022-08-04 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
|
US20220305107A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi
|
WO2020255035A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
|
US20220305114A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
|
WO2020255042A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
|
WO2020255019A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
|
WO2020255016A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
CA3141003A1
(en)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
|
WO2020255018A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Hepatitis b virus (hbv) vaccines and uses thereof
|
WO2020255013A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
|
AU2020295012A1
(en)
|
2019-06-18 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis B virus (HBV) vaccines and anti-PD-1 or anti-PD-L1 antibody
|
WO2020255022A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
|
WO2020255010A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
|
TW202114732A
(en)
|
2019-06-20 |
2021-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
|
EP3986457A1
(en)
|
2019-06-20 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
|
US11878167B2
(en)
|
2020-05-04 |
2024-01-23 |
Btl Healthcare Technologies A.S. |
Device and method for unattended treatment of a patient
|
EP4146335A1
(en)
|
2020-05-04 |
2023-03-15 |
BTL Healthcare Technologies a.s. |
Device and method for unattended treatment of a patient
|
IL298874A
(en)
|
2020-06-12 |
2023-02-01 |
Univ Rochester |
ENCODING AND EXPRESSION OF ACE-tRNAs
|
TW202216190A
(en)
|
2020-07-08 |
2022-05-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
Rna replicon vaccines against hbv
|
TW202245809A
(en)
|
2020-12-18 |
2022-12-01 |
美商詹森藥物公司 |
Combination therapy for treating hepatitis b virus infection
|
AU2021412833A1
(en)
|
2020-12-28 |
2023-07-06 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
US11896816B2
(en)
|
2021-11-03 |
2024-02-13 |
Btl Healthcare Technologies A.S. |
Device and method for unattended treatment of a patient
|
WO2023150753A1
(en)
|
2022-02-07 |
2023-08-10 |
University Of Rochester |
Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
|
WO2023233290A1
(en)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Rnai agents targeting pd-l1
|